alexa Pharmaceutical Development Of Injectable Nanomedicine Targeting Breast Cancer
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

13th International Conference and Exhibition on Nanomedicine and Pharmaceutical Nanotechnology
July 24-25, 2017 | Rome, Italy

Igor Chourpa
Université Francois Rabelais de Tours, France
Keynote: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439-C1-048
Abstract
Anti-cancer theranosis (therapy and diagnosis) using nanomedicine is a promising perspective, related to a possibility to combine several diagnostic and therapeutic functions in order to potentiate them. Superparamagnetic iron oxides (SPIONs) are often used as nanomedicine platforms due to the possibility to stimulate their intratumoral staining and drug delivery with help of a magnetic field as well as to contrast tumors on Magnetic Resonance Imaging (MRI). In order to inject SPIONs intravenously, their biocompatibility and efficiency has to be improved by surface coating with neutral biocompatible polymers like Polethylene Glycol (PEG) functionalized with molecular cancer targeting ligands like peptides and antibody fragments. We are developing PEGylated and bio-functionnalized injectable nanovectors based on PEGylated SPIONs. Their polymeric shell is covalently coupled with membranotropic cell-penetrating peptides gH625 and/or with scFv fragments of antibody trastuzumab which binds specifically to membranes of HER2 positive breast cancers. The nanosystems can thus act as vectors of chemotherapeutic drugs of anticancer-active siRNA. The pharmaceutical development strategy we apply includes not only a rational design of the nanosystems but also step-by-step optimization of their structure in order to reach the better biocompatibility/bioactivity. For each nanoform, tens of independent batches were generated and their physicochemical characteristics (size and zeta potential, chemical composition and structure) were established. Prior to in vivo essay on breast cancer xenografts in mice, the nanoforms interaction with cancer cells has been studied in vitro, on various cancer cell lines, overexpressing or not cancer-specific receptors. Comparison of biological behavior of the ligand free vs. ligand carrying PEGylated nanovectors allowed us to demonstrate that the moderate presence of ligands was not able to affect the nanomedicine forms size and zeta potential. Nevertheless, the bio-ligands enhanced the nanomedicine-cell interactions, both quantitatively (intracellular accumulation) and qualitatively (internalization, subcellular distribution and cargo delivery/ transfection).
Biography

Igor Chourpa is Director of Analytical Chemistry Department at the Faculty of Pharmacy of the University François Rabelais of Tours, France, and Head of the research group “Nanomedicine & Nanoprobes” EA6295. This group develops nanomedicines for anticancer theranosis, i.e. diagnosis by medical imaging and therapy by delivery of chemotherapy or siRNA. His particular expertise domain is optical microspectroscopy (Raman, surface-enhanced Raman and fluorescence) and spectral imaging. He has authored 62 publications in peer-reviewed journals. He is member of Editorial Boards of J. Anal. Meth. Chem. (Hindawi) and Int. J. of Nanopart. Nanotechnol. (Helics).

Email: igor.chou[email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]e.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords